Podcasts about Cart

Take a look at Joni's newest book: "Keeping Faith When Life Hurts." Order it here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Picolé De Limão é um quadro do canal Não Inviabilize. Aqui você ouve as suas histórias misturadas às minhas!Use a hashtag #Protecao e comente a história no nosso grupo do telegram: https://t.me/naoinviabilizePUBLICIDADE MERCADO LIVRE Para todos os pais que falam que não precisam de nada, mas na verdade estão precisando de tudo: ofertas de até 70% OFF, até 21x sem juros com cartão Mercado Pago e muito mais só no Mercado Livre. Corre pro app fazer comprittas: https://bit.ly/4f7Umc5 Campanha válida até 09/08/2026. Cartão de crédito sujeito à aprovação. Parcelamento elegível a produtos selecionados. Veja condições do Vale Troca em mercadolivre.com.br/l/valetroca. Ver mais condições em Dia dos Pais.QUER OUVIR MAIS HISTÓRIAS? BAIXE NOSSO APLICATIVO EM SUA LOJA APPLE/GOOGLE, CONHEÇA NOSSOS QUADROS EXCLUSIVOS E RECEBA EPISÓDIOS INÉDITOS DE SEGUNDA A SÁBADO: https://naoinviabilize.com.br/assineEnvie a sua história bem detalhada para naoinviabilize@gmail.com, seu anonimato será mantido, todos os nomes, profissões e locais são trocados para preservar a sua identidade.Site: https://naoinviabilize.com.brTranscrição dos episódios: https://naoinviabilize.com.br/episodiosYoutube: https://youtube.com/naoinviabilizeInstagram: https://www.instagram.com/naoinviabilizeTikTok: https://www.tiktok.com/@naoinviabilizeX: https://x.com/naoinviabilizeFacebook: https://facebook.com/naoinviabilizeEdição de áudios: Depois O Leo Corta MultimídiaVinhetas: Pipoca SoundVoz da vinheta: Priscila Armani

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of treating multiple myeloma, focusing on two challenging cases from the community. Joined by experts Marco Davila, MD PhD, from Roswell Park Comprehensive Cancer Center and Krina Patel, MD MSc, from MD Anderson Cancer Center, they discuss the nuances of treatment options for patients experiencing disease relapse post-transplant and disease progression while on maintenance therapy.   Key topics included: The importance of thorough workup and repeat cytogenetics in high-risk multiple myeloma patients The debate between CAR T-cell therapy and bispecific antibodies as treatment options Strategies for managing patients with comorbidities and the role of shared decision-making in treatment planning Insights into the side effects associated with CAR-T and bispecific therapies, including infection risks and neurological symptoms Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Join us as we explored the latest advancements in multiple myeloma treatment and the exciting potential for achieving long-term remission and even cure in select patient populations.   Don't forget to like, subscribe, and hit the notification bell for more insightful discussions on oncology! #MultipleMyeloma, #CARTtherapy, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers  

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of diffuse large B-cell lymphoma (DLBCL) for 2026, updating their prior coverage to reflect several recent practice changes.The discussion began with clinical presentation, emphasizing the classic B symptoms—weight loss, night sweats, fatigue, and fever—alongside painless, rapidly enlarging lymphadenopathy. They noted that approximately 30% to 40% of cases present with extranodal involvement (gastrointestinal, central nervous system [CNS], or thyroid) and stressed that an excisional biopsy is required, as fine-needle aspiration cannot preserve the architecture needed for histologic grading.Turning to classification, Drs Armstrong and Tawagi reviewed germinal center vs non-germinal center origin, with non-germinal center disease carrying a worse prognosis. They characterized double-hit lymphoma, triple-hit lymphoma, and double-expressor lymphoma, the last conferring an intermediate prognosis.Regarding workup, they recommended full-body PET scans, laboratory evaluation for tumor lysis syndrome, hepatitis B testing before anti-CD20 therapy, baseline echocardiography before anthracyclines, and lumbar puncture with intrathecal methotrexate in patients at high risk for CNS relapse. They also reviewed updated staging systems.For treatment, they explained that limited-stage disease is now stratified by the stage-modified International Prognostic Index (IPI), guiding abbreviated vs full R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone). In advanced disease, 6 cycles of R-CHOP remains standard, with polatuzumab vedotin-piiq (Polivy) plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) now a category 1 regimen for patients with an IPI of 2 or greater. They also addressed dose-adjusted regimens for double-hit disease, CAR T-cell therapy, and bispecific antibodies in the relapsed/refractory setting, as well as surveillance recommendations, cautioning against routine PET imaging.

O chamado "contrato de gaveta", prática ainda bastante utilizada na compra e venda de imóveis, pode trazer sérios prejuízos para compradores e vendedores. O alerta é da tabeliã do Cartório de Notas e Protestos de Títulos de Lauro Müller, Ingrid Brandão Sartor, que participou de entrevista na Rádio Cruz de Malta e explicou os riscos de formalizar negociações apenas por meio de contratos particulares, sem a devida escritura pública e registro. Segundo Ingrid, apesar das campanhas de conscientização realizadas pelo cartório, o procedimento continua sendo comum no município. Ela explica que, na maioria das vezes, o comprador opta pelo contrato de gaveta porque pretende pagar o imóvel de forma parcelada e acredita que não é possível fazer a escritura antes da quitação. "Ainda estamos vendo muitos contratos de gaveta sendo feitos. A pessoa vai tentar comprar um imóvel, não deseja fazer a escritura na hora porque quer pagar em prestações. Então ela pega um modelo na internet, reconhece a assinatura em cartório e deixa o contrato literalmente na gaveta", relata. A tabeliã ressalta que o reconhecimento de firma não significa que o documento fique arquivado no cartório. De acordo com ela, esse é um dos principais equívocos cometidos por quem utiliza esse tipo de contrato. "O contrato de gaveta não fica no cartório. Nós apenas reconhecemos a assinatura, mas não guardamos o documento. Só a escritura pública é que dá segurança e fica conosco para sempre", explica. Além da possibilidade de perda do documento, Ingrid destaca que a situação pode se tornar ainda mais complexa caso o vendedor faleça antes da regularização da negociação. "No contrato de gaveta, a propriedade ainda está no nome de quem vendeu. Se o vendedor falecer, o imóvel terá que ser inventariado, passará pelos herdeiros e poderá exigir uma ação judicial e gastos complementares", afirma.

July 19, 2026

Popp Talk with Mary Jane Popp Biotech Breakthroughs, Hidden Pain, and the Truth We Struggle to Tell Guests, Tim Harris and Michelle May A Potpourri of Health, Science, and Self-Understanding In this episode of Popp Talk, host Mary Jane Popp introduces a wide-ranging “potpourri” show covering biotechnology, health, therapy, and the hidden struggles people sometimes carry beneath the surface. She begins by setting up an interview with Tim Harris, author of In Pursuit of Unicorns: A Journey Through 50 Years of Biotechnology, and later introduces Michelle May, psychotherapist and author of What I Couldn't Tell My Therapist. The episode moves from the evolution of biotech and medical innovation to emotional repression, chronic pain, social media misinformation, and the importance of personal responsibility. Tim Harris on Biotechnology and the Pursuit of Unicorns Mary Jane's first guest, Tim Harris, defines biotechnology as the combination of biology and technology, beginning with recombinant DNA and monoclonal antibodies. He explains that his book title uses the word “unicorns” because biotech companies can become billion-dollar enterprises, though some valuations may prove more mythical than real. Harris presents biotechnology not only as a scientific field but also as a business story shaped by companies, capital, invention, risk, and the long effort to turn scientific tools into useful products. Recombinant DNA, Monoclonal Antibodies, and Gene Editing Harris walks listeners through the development of recombinant DNA, explaining how scientists learned to combine pieces of DNA and use bacteria such as E. coli to produce important proteins like insulin and growth hormone. He also explains monoclonal antibodies as single antibodies made by cloned cells, first useful for diagnostics and later for therapies. The conversation then turns to gene editing, including CRISPR-Cas9 and its use in sickle cell disease, which Harris describes as life-changing for patients whose lives revolve around managing pain and disease. Cancer, mRNA Vaccines, AI, and the Risks of Innovation Mary Jane and Harris discuss why cancer remains difficult to treat, with Harris explaining CAR T-cell therapy, its success in certain leukemias and lymphomas, and the continuing challenge of solid tumors such as breast, prostate, and colon cancer. He also connects nanotechnology to COVID-19 mRNA vaccines, describing lipid nanoparticles as the delivery system for messenger RNA. The conversation expands into new COVID strains, vaccine updates, artificial intelligence, risk assessment, and the limits of prediction in biology. Harris emphasizes that while AI can help analyze data and predict viral changes, drug discovery and development remain experimental sciences. Michelle May's Story of Chronic Pain and Repressed Emotion The second major interview features Michelle May, who shares that she woke up in 2007 with a headache that lasted six years. Doctors eventually found a Chiari malformation, and after two brain surgeries, her head pain improved dramatically. Still, some headaches remained, and May says she later learned through intensive dynamic therapy that repressed emotions also contributed to her pain. She explains that anger, grief, guilt, and love can be pushed out of awareness when people grow up in environments where certain feelings do not feel safe, but those emotions may still remain in the body. What People Cannot Tell Their Therapist May explains that the title What I Couldn't Tell My Therapist has two meanings: the painful family stories she feared would feel like betrayal, and the truths she had not yet admitted to herself. She describes how patients may minimize or filter their experiences, especially when they love the people who hurt them. Mary Jane presses her on how therapy helps uncover those hidden barriers, and May explains that she watches for avoidance patterns, such as looking away, intellectualizing, minimizing pain, or struggling to stay connected while discussing intimacy and emotion. Pain, Anxiety, Opioids, Social Media, and Responsibility The interview broadens into the overlap between physical pain and emotional pain, with May stressing that medical causes should always be ruled out first before exploring emotional processes. She distinguishes between feelings and actions, explaining that anger is a bodily experience while harmful behavior is a choice. The conversation also covers chronic pain, opioid dependence, the mind-body connection, social media misinformation, fact-checking, political and cultural falsehoods, and the difficulty people have admitting they were wrong. The episode closes with May encouraging people to find a therapist they trust, while Mary Jane emphasizes comfort, accountability, and the need to stop blaming others when personal responsibility is required.

The Alan Cox ShowSee omnystudio.com/listener for privacy information.

Ever had an accident like this? Listen to this ONE story or ... "BINGE" 15 minutes for MORE encouragement!  If you like my stories please support the ministry by following me on Spotify! Love to hear from you!  Email: encouragement971@gmail.com

Smarter Ecommerce Promotions with RevlifterKey takeaways:Blanket discounting often reduces profitability and can negatively affect customer experience.Intent-based personalisation enables retailers to engage shoppers with more relevant messages at the right moment.Personalisation isn't only about promotion; it can also support education, reassurance and product discovery.Smarter popup strategies can increase conversions while significantly reducing unnecessary discounts.Premium brands can use behavioural targeting to improve customer experience without relying on discounts.Creative gamification offers opportunities to increase engagement beyond traditional prize wheels.Measuring incrementality through robust testing is essential for understanding the true commercial impact of personalisation.Granular A/B testing and audience segmentation help retailers continuously optimise campaigns and maximise performance.In this episode, we explore how ecommerce brands can move beyond blanket discounting to deliver more relevant, profitable customer experiences. The conversation focuses on why traditional promotional strategies often frustrate shoppers, how intent-based personalisation is changing the way retailers engage customers and how brands can measure the true impact of their campaigns.Our guest is Dan Bond from Revlifter. Revlifter's technology helps retailers personalise onsite marketing campaigns based on real-time customer intent rather than relying on broad promotional tactics.A key theme throughout the episode is the downside of poorly targeted promotions. Irrelevant offers can damage trust and create frustration; for example, when loyal customers are excluded from incentives designed only for new shoppers.We cover (rant about) the common mistakes retailers make, the commercial impact of those decisions and why brands need to create more intelligent promotional strategies.We also discuss the growing importance of customer intent signals. Instead of treating every visitor the same, Dan explains how retailers can identify whether a shopper is actively ready to purchase or still in the discovery phase, allowing brands to tailor messaging and offers accordingly.Moving beyond discounts, the discussion highlights how intent scoring can also power non-promotional experiences, such as providing buying guidance, product advice and reassurance during more complex purchasing journeys. This demonstrates how personalisation can improve customer experience without sacrificing margin.Dan shares a real-world success story from Sportshoes. Discover how a refined popup strategy delivered a 7% uplift in conversions while suppressing more than 2,000 unnecessary discounts, resulting in savings of approximately £25,000. Our attention then turns to premium brands, where discounting is often less appropriate. Using examples such as Radley, we discuss how exit-intent campaigns can be used across product listing pages, product pages and the cart to deliver value through personalised messaging, product recommendations or reassurance rather than price reductions.Another topic is gamification, challenging the assumption that engagement begins and ends with the familiar "spin-to-win" mechanic. The discussion explores alternative campaign formats and creative approaches that ecommerce teams can test to increase engagement and conversion while maintaining brand value.

More investigation into the strange sets of "cart ruts" we explored in the Phrygian Valley in Turkey. We show more drone footage and photos, look at examples of "cart ruts" from the "Oregon Trail" in Wyoming, as well as actual ruts in mud for comparison. We read more emails with suggestions and ideas and discuss them. Thank you all for your emails and comments! The ruts are a fascinating and enduring mystery.   Support us on Patron or PayPal by going through our support page here: https://www.brothersoftheserpent.com/support   Chapters 00:00 Introduction and episode overview 02:00 Initial observations and setting the scene 04:04 Discussion of recent field visits and findings 06:02 Analysis of the physical characteristics of the ruts 07:59 Theories about water erosion and natural formation 10:04 Possible ancient vehicle or machine origins 11:57 Geological processes like calcification and erosion 13:53 Comparison with Oregon Trail and other historical ruts 15:57 The role of environmental changes and climate shifts 17:59 Discussion of recent scientific insights and hypotheses 19:51 Summary of key points and ongoing questions 02:30 Analysis of Terrain and Material Evidence 04:59 Hypotheses: Watercraft, Sleds, and Carts 10:04 Geological and Material Insights 15:04 Historical Context and Theories 19:51 Practical Considerations and Experiments 25:07 Summary of Key Findings and Open Questions

Imagine a dark warehouse. Racks and racks of devices with wires, tubes, and electronics sticking out. The next AI data center? No. This is Lila Sciences‘ dream for the future of science. A dark warehouse full of AI-guided robotics and lab equipment, cranking out new experiments 24/7, building toward a scientific superintelligence.Their automated lab is almost hypnotizing to watch. They have floating plates zipping around on Wall-E-esque tracks, used vision-language models to control Windows 95 boxes, and created the world's largest collection of voided warranties. In the process they've built a massive library of scientific reasoning tokens. Over 10 trillion of them, all experimentally validated.No warranties were voided in the making of this videoTo say Lila is ambitious is an understatement. Their goal is a scientific superintelligence wired directly into the wet lab. They are all in on the bitter lesson, and the thesis follows from it: a lab is an infinite token generator. Produce data at scale, and the synergies give you a general reasoner that can tackle any scientific problem. They are committing hard. Biology, chemistry, drug discovery, and materials science, all at the same time. Time will tell if it works, but it is an exciting hypothesis.In our latest episode we sat down with Lila's very own Andy Beam (CTO) and Rafa Gómez-Bombarelli (CSO, physical sciences) and went on a journey through the possibilities of AI-run science, almost as wide-ranging as Lila's goals.Did we mention they do both materials science and biology? In the same AI science factory? Same time, same lab, same AI. Finally a guest who can settle a long-running debate we've had amongst ourselves: is biology or materials science harder?Watch to find out!We discuss:* The internet is spent, science is next. Why Lila thinks the scientific method is the last untapped internet-scale dataset, and why they treat RL as a data generation mechanism with nature as the verifier.* The lab as a data center. Instruments as nodes on a graph, a magnetically levitating “PCI bus” transport layer between them, orchestration as a slurm queue. Andy is not short on analogies.* Why Lila insists it is not an automation company. They optimize for flexibility and generalizability over raw throughput, which means humans stay below the API line wherever automating does not pay.* Your experiment has a runtime. We put Escalante Bio's question to Andy: if science is the token generator, what is the runtime of your data collection? His answer, in short, is that you cannot make the ribosome go faster. Why Lila bets on fast round-over-round iteration rather than big noisy multiplexed screens, and how Rafa's team rebuilt a gas sorption measurement to run roughly 2,500x faster.* What is actually in 10 trillion scientific tokens. Not sequences. Experimentally verified reasoning traces, a kind of data that Andy argues exists on the internet in quantities that round to zero.* Breadth as a path to depth. Small molecule chemistry priors transferring to metal organic frameworks for carbon capture, and the claim that the general model beats domain-specific models sample for sample.* If you have the data, what do you need the model for? Sri Kosuri's koan about the ML-for-drug-discovery business model, and Andy's answer: the coding model got better because it also read Shakespeare and carnitas recipes.* The serendipity they want to automate. Emily Whitehead survived the first pediatric CAR-T cure only because the doctor treating her happened to know, from pediatric arthritis, which antibody would blunt her IL-6 response. Roll that dice again and you probably lose her. Breadth is how you stop depending on luck.* Move 37 for catalysts. Model suggestions for platinum-group-free electrocatalysts that went from boring, to what a 40-paper expert called stupid, to the best performers they have made.* Six months to in vivo CAR-T data in non-human primates, and the zero-FTE virtual startup commercial model that fell out of it. For context on why that number is startling, AbbVie paid $2.1B for Capstan on the strength of preclinical in vivo CAR-T data.* You cannot have scientific superintelligence if you are just a good test taker. Ken Stanley, who wrote Why Greatness Cannot Be Planned, runs open-endedness at Lila. RL at scale gives you a ruthlessly Vulcan problem solver. Machine creativity is a different thing, and it is the part nobody has solved.* The chain of thought is an unreliable narrator. The model reasons in latent space and only emits tokens. Sometimes it skips the experiment entirely and is still right. So how much do you trust the reasoning versus the verifier?* Reward hacking when the rollout is physical. Chains of thought that collapse into repetition, and a model that got annoyed and swore at the scientist who kept asking it to redo a plate map. What happens when a pathological loop has a wet lab inside it?* The bittersweet lesson. Rafa's inversion of the bitter lesson: in AI, scaling is a roadmap. In materials, scaling is a filter, because only the things that scale end up mattering.* Not your typical Flagship company. Why a famously single-asset biotech incubator spun out a platform bet, and Andy's line that if Lila called itself a biopharma it would have a top-three GPU cluster.* Bottlenecks they would remove by fiat. Sim-to-real for physics-based simulation, and the fact that RL training runs at roughly 5% mean FLOP utilization.Watch on YouTube: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.latent.space/subscribe

People with rare, severe autoimmune diseases often live for years with progressive, disabling conditions managed by chronic immunosuppression that rarely addresses the underlying cause. Kyverna is developing an autologous CAR T-cell therapy designed to deliver a deep immune reset by broadly depleting pathogenic B cells, followed by repopulation with naïve, non-pathogenic B cells and normalization of T-cell function and cytokine profiles. This approach has the potential to enable durable remissions and discontinuation of background immunosuppressive therapies after a single infusion. The company's pipeline is focused on neuroimmunology, with lead programs in generalized myasthenia gravis and stiff person syndrome. Warner Biddle, CEO of Kyverna Therapeutics, discusses the company's B cell–targeting cell therapy platform, the range of autoimmune diseases it aims to address, and its next-generation therapies in development.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Haris Sohail and Lucas Kühne on their latest articles published in volume 147 issue 21 of Blood. In this CME article titled, "Retrospective, Real-World Study of IV Iron Use to Treat Iron deficiency Anemia During Acute Infection",  Sohail et al show that IV iron given during acute infection with iron deficiency anemia is associated with improved 14-day and 90-day survival as well as hemoglobin recovery. Although this report has the limitations of a retrospective study, these findings challenge current practice and support randomized trials that include patients with infection. In "Revisiting Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Purpura", Kühne et al show in a multicenter registry study of 204 patients that refractoriness during caplacizumab treatment in immune TTP is uncommon and, when observed, is typically associated with confounding clinical factors. These findings underscore the importance of careful clinical reassessment and evaluation for alternative etiologies in patients with delayed platelet recovery, rather than attributing such cases to true treatment resistance.

Send us Fan MailFor decades, the war on cancer has focused on destroying cancer cells directly - with chemotherapy, radiation, and targeted drugs. But what if the future of cancer treatment is not about attacking cancer ourselves...but teaching our own immune system to do it for us?Today we're exploring a new generation of immunotherapies designed to turn the body's own defenses into a precision weapon against cancer.Over the past decade, immunotherapies such as checkpoint inhibitors and CAR-T cell therapies have transformed the treatment landscape for many cancers. But major challenges remain - including limited response rates, treatment resistance, toxicity, and the enormous complexity and cost of manufacturing many next-generation therapies.Our guest today believes the next breakthrough may come from a new generation of personalized immunotherapies designed to activate a patient's own immune system against their cancer - while also being manufactured as an accessible, off-the-shelf treatment.Joining us is Dr. William Williams, MD - President and CEO of BriaCell Therapeutics ( https://briacell.com/ ).Dr. Williams brings more than 35 years of experience spanning academia and the biopharmaceutical industry. He has helped advance numerous medicines from discovery through clinical development, including work contributing to therapies such as Jakafi and Olumiant during his time at Incyte, and multiple oncology programs during his career at GlaxoSmithKline.Before entering industry leadership, Dr. Williams was a researcher at the University of Pennsylvania focused on molecular immunology, receptor biology, and early DNA vaccine approaches.Today we'll discuss the evolution of cancer immunotherapy, BriaCell's Bria-IMT platform, the challenges of treating advanced breast cancer, and whether the future of oncology lies in creating therapies that can truly mobilize each patient's own immune system.#CancerResearch #CancerImmunotherapy #Immunotherapy #CancerTreatment #Oncology #PrecisionMedicine #PersonalizedMedicine #Biotechnology #Biotech #LifeSciences #DrugDiscovery #ClinicalTrials #BreastCancer #MetastaticBreastCancer #CancerVaccine #CellTherapy #TumorImmunology #TCells #ImmuneSystem #MedicalInnovation #FutureOfMedicine #HealthcareInnovation #BiomedicalResearch #Pharma #PharmaceuticalInnovation #SciencePodcast #ProgressPotentialAndPossibilities #PPPShowSupport the show

There is some recent research that's testing out cancer treatments that can utilize the power of our immune systems to attack cancer cells. It's called CAR T-cell therapy and it involves programming immune cells to target and attack cancer in the body. Here to explain more is Dr. Shreya Shukla, a biomedical engineer specializing in this treatment. But first, host Dr. Samantha Yammine will separate hype from fact when it comes to one of the internet's most recent fixations: peptides. Later, Sam digs into a study trying to figure out how pigeons find their way home on a cloudy day. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. Terms apply. Hosted on Acast. See acast.com/privacy for more information.

Preparing for postpartum doesn't have to be overwhelming. In this episode, Dr. Morgan shares everything she's putting in her postpartum cart as she prepares for baby number five, including the products she swears by, the items she skips, and why less is often more.From breastfeeding essentials, perineal healing, baby gear, and postpartum supplements to nutrition, mental health, and recovery, this episode is a practical guide for building a postpartum setup that truly supports both mom and baby.Whether you're expecting your first baby or your fifth, you'll walk away knowing what actually deserves a spot on your registry, and what doesn't.00:00 Trailer + Intro02:15 Why You Don't Need Everything07:46 Breastfeeding Essentials09:41 Best Products for Nipple Healing13:44 When to Use a Nipple Shield21:07 Milk Collection & Breast Pads27:24 Active Skin Repair29:47 Electrolytes for Recovery32:23 Milk Supply Support34:29 Nursing Bras35:09 Perineal Healing Essentials39:48 Baby Essentials You Actually Need41:15 Favorite Diapers & Wipes44:35 Baby Clothes & Sleep Setup48:29 Pacifiers & Baby Carriers54:09 Postpartum Comfort & Recovery56:44 Best Postpartum Supplements58:37 Nourishing Herbs & Tonics60:59 Stress & Mental Health Support68:56 Nutrition & Meal Planning74:16 What I Don't BuyResources From This Episode:Get all of the supplies mentioned in this episode here: https://milkmedicine.com/postpartum-cart-links/Healthy As A Mother Podcast | YouTubeHealthy As A Mother Podcast | InstagramHealthy As A Mother Podcast | TikTokHealthy As A Mother Podcast | Merch StoreFind more from Dr. Leah:Dr. Leah Gordon | InstagramDr. Leah Gordon | WebsiteWomanhood Wellness | WebsiteFind more from Dr. Morgan:Dr. Morgan MacDermott | InstagramDr. Morgan MacDermott | WebsiteUse code HEALTHMOTHER and save 10% at Ninni Co.Use code HEALTHYMOTHER and save 10% at EarthleyUse code HEALTHYMOTHER and save 15% at RedmondFor 20% off your first order at Needed, use code HEALTHYMOTHERSave $260 at Lumebox, use code HEALTHYASAMOTHERUse code HAAM and save 10% at Fond

Sam Harris speaks with Siddhartha Mukherjee about the science of cancer. They discuss the updated edition of The Emperor of All Maladies, whether cancer is one disease or many, why prevention is so hard, inflammation and air pollution as carcinogens, the myth that cell phones cause cancer, liquid biopsies and Bayesian reasoning, immunotherapy and CAR T cells, drug pricing, the promise of AI in drug discovery, the state of American medical science, and other topics. If the Making Sense podcast logo in your player is BLACK, you can SUBSCRIBE to gain access to all full-length episodes at samharris.org/subscribe.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Hoje o papo é sobre o SERP, o Sistema Eletrônico dos Registros Públicos! Neste episódio, conversamos sobre como a plataforma Meu Registro pretende simplificar o acesso aos serviços de cartório e integrar diferentes tipos de registros públicos. O papo também passa por interoperabilidade, APIs, segurança, assinaturas digitais, modernização dos cartórios e os desafios de conectar sistemas antigos em uma única porta de entrada. Vem ver quem participou desse papo: Paulo Silveira, o host que usa a palavra governança Vinny Neves, cohost, dev e professor na Alura Fabrício Carraro, co-host do IA Sob Controle, Program Manager da Alura, autor de IA e host do podcast Carreira Sem Fronteiras Rodrigo Gonçalves de Souza, juiz auxiliar da Corregedoria Nacional de Justiça, no CNJ Rodrigo Pinho, gerente de projetos de tecnologia no Operador Nacional de Registro de Títulos e Documentos e de Pessoas Jurídicas (ON-RTDPJ)  Links:  Sistema Eletrônico dos Registros Públicos (SERP) Meu Registro Conselho Nacional de Justiça (CNJ) Corregedoria Nacional de Justiça Operador Nacional de Registro de Títulos e Documentos e de Pessoas Jurídicas (ON-RTDPJ) Operador Nacional do Registro Civil de Pessoas Naturais (ON-RCPN) Portal Oficial do Registro Civil Operador Nacional do Sistema de Registro Eletrônico de Imóveis (ONR) Lei nº 14.382/2022 Central Nacional de Registro de Títulos e Documentos e de Pessoas Jurídicas Atos normativos do Conselho Nacional de Justiça Infraestrutura de Chaves Públicas Brasileira (ICP-Brasil) Plataforma Digital do Poder Judiciário Brasileiro (PDPJ-Br) Toda revolução tecnológica começa com quem antecipa o futuro e transforma ideias em soluções de alto impacto. Conheça os cursos da Alura + FIAP Skills & Go: Agentic Engineering, Building AI Products, e AI Data Strategy. Saiba mais sobre o Skills & Go. Vá para o Vale do Silício com Paulo Silveira, Marcell Almeida, Fabrício Carraro e Marcus Mendes na “Imersão IA Sob Controle e Alura no Vale do Silício“! Vagas limitadas, corra para reservar a sua. TechGuide.sh, um mapeamento das principais tecnologias demandadas pelo mercado para diferentes carreiras, com nossas sugestões e opiniões. #7DaysOfCode: Coloque em prática os seus conhecimentos de programação em desafios diários e gratuitos. Acesse https://7daysofcode.io/ Produção e conteúdo: Alura Cursos de Tecnologia – https://www.alura.com.br Edição e sonorização: Rede Gigahertz de Podcasts

What if the answer to solid tumor therapy isn't about making immune cells smarter—but about rethinking what a therapeutic cell can do For years, mesenchymal stem cells (MSCs) have turned heads for their ability to home in on damaged tissue, yet their clinical utility has lagged behind the hype. What would it take to transform MSCs from passive healers into precision vehicles for next-generation cancer treatment?This week, David Brühlmann sits down with Jun Yung Woo, Co-Founder of AGEM Bio, who's devoted nearly two decades to decoding and reimagining the potential of MSCs. From engineering stress-resilient cells to pioneering dual-payload therapeutic platforms, Jun Yung Woo bridges fundamental biology and real-world clinical translation.Topics discussed:The case for understanding cell biology before focusing on process scale-up in bioprocessing (02:38)Jun Yung Woo's personal and scientific journey toward developing engineered MSC therapeutics (04:36)How MSCs sense their environment and exert therapeutic effects via secreted factors, rather than tissue replacement (08:28)Key differences between MSC therapies and immune cell therapies like CAR T cells (10:35)Overview of non-viral engineering platforms, and the importance of intracellular trafficking for modifying MSCs (12:23)Design of AGEM Bio's dual-payload MSC product (cytosine deaminase and interferon beta) to induce highly localized tumor stress and immune activation (14:10)Strategies for controlling MSC targeting and minimizing off-target effects, including the use of prodrug activation and localized cell delivery (17:23)Study results from treating companion animals with engineered MSCs, and observations of tumor regression and possible signs of immune memory (20:29)Open questions about the durability of antitumor responses and future directions for clinical research (22:34)Smart insight: Jun Yung Woo challenges the rush toward bioprocess scale-up, arguing that a deeper understanding of cellular biology should come before manufacturing cells at scale. This episode explores how scaling the wrong biology can derail entire therapeutic platforms—and why aligning process development with cellular function may be critical for clinical success.These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason FosterConnect with Jun Yung Woo:LinkedIn: www.linkedin.com/in/junyungwooAGEM Bio website: www.agem.bioEmail: yung@agem.bioSupport the show

Guest: Dr. Andrew Hogan is a Professor and Principal Investigator of the Obesity Immunology Research Group at Maynooth University. He discusses how obesity drives chronic inflammation and immune dysfunction, increasing the risk of diseases such as diabetes and cancer, while highlighting the immune system’s role in disease progression. He also explains how GLP-1 therapies improve both metabolism and immune function, offering new insights into obesity treatment. Featured Products and Resources: Request your free EasySep sample and share your experience for a chance to win prizes worth up to $3,000! Win 350 US dollars or equivalent toward refreshments to fuel your journal club discussions. The Immunology Science Round Up Innate Immunity Predicts Symptoms – Stronger innate immune responses predisposed people to influenza symptoms while also promoting antiviral immune activation. Broad HIV Neutralization #1 – A novel HIV immunogen induced broadly neutralizing antibodies in macaques, providing a promising blueprint for HIV vaccine development. Broad HIV Neutralization #2 – A germline-targeting vaccine induced broadly neutralizing HIV antibodies in nonhuman primates. CAR-T Targets Glioblastoma – A dual-targeting CAR-T therapy achieved durable glioblastoma control in preclinical models. Image courtesy of Dr. Andrew Hogan Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

July 12, 2026

Johnny Mac shares five good news stories: Steve, a paralyzed miniature Australian shepherd in Denver whose wheelchair was stolen from a porch, received a donated new 2026 model from Walkin' Pets after the plea on Instagram drew over 150,000 views. In the UK, early clinical trials at University College London Hospitals found CAR-T therapy can reset the immune system and put severe lupus into remission, with patient Katie describing dramatic improvement after 30 years of disease. In California, 24-year-old Ishan set a Guinness World Record by solving two Rubik's Cubes during a single skydive, including one in 120 mph free fall, on his first day skydiving. Ohio deputies in Butler County rounded up seven wandering goats, but one mischievous goat escaped into the woods. An orange cat interrupted the Imperial Russian Ballet Company's Romeo and Juliet by strolling onstage and interacting with the dancers.5 Good News Stories is a daily podcast with five positive, uplifting news stories to brighten your day. New episodes every day. Follow on Apple Podcasts, Spotify, or wherever you listen. Part of the Caloroga Shark Media networkJohn also hosts Daily Comedy NewsUnlock an ad-free podcast experience with Caloroga Shark Media!  For Apple users, hit the banner which says Uninterrupted Listening on your Apple podcasts app. Subscribe now for exclusive shows like 'Palace Intrigue,' and get bonus content from Deep Crown (our exclusive Palace Insider!) Or get 'Daily Comedy News,' and '5 Good News Stories' with no commercials! Plans start at $4.99 per month, or save 20% with a yearly plan at $49.99. Join today and help support the show!Get more info from Caloroga Shark Media and if you have any comments, suggestions, or just want to get in touch our email is info@caloroga.com

Everything begins with hearing and chanting. When devotees take to the practice and make vows, there is a feeling of exhilaration because we have unlimited potential. There may be times at which we feel waylaid by our own mind, senses, or other occupational obligations, and therefore it's helpful to come back to remember what the horse is and what the cart is, and always put the horse before the cart. For instance, there are ways of fading away from good chanting, there are ways of fading away from reading and hearing Prabhupāda's books because there are pressing matters in life, and they can then take precedence over time. And then we may put off our chanting, or we may put off hearing from the Śāstras for the sake of attending to some urgent matter. We might do it one day, and then two days, and then it becomes a habit, and then we wonder, "Why am I not feeling ecstasy?" and "What happened to my relationship with Kṛṣṇa?" and it could come to, "Why am I doing this anyway?" So, as a reminder, we have this saying: "Don't put the cart before the horse," because we should discriminate on a moment-to-moment basis and a day-to-day basis to remember what's most important. A practice which is most highly recommended is to study the Śrīmad-Bhāgavatam, the Bhagavad-gītā—all of these literatures that Prabhupāda left behind for us—in the association of devotees. And as Prabhupāda said, you should discuss them thoroughly, threadbare. If you have an old coat that you are attached to and you've worn it so many times, you might notice it becomes threadbare, meaning you'll start to see indentations where you have worn it, and maybe some of the parts wear out, and you put a little patch there—an old tweed jacket, sort of the professorial look of an old worn jacket. Prabhupāda wanted us to discuss what is in the literatures he left behind, share realizations, and to go on hearing regularly. When we feel our sense of enthusiasm flagging, then the remedy is to increase what is most important, and that's hearing and chanting. Someone might say, "Well, I don't have time for all that," but it's not time; it's taste. But how do you get the taste? You have to...(0:07:45) ------------------------------------------------------------ To connect with His Grace Vaiśeṣika Dāsa, please visit https://www.fanthespark.com/next-steps/ask-vaisesika-dasa/?utm_source=youtube&utm_medium=video&utm_campaign=launch2025 https://vaisesikadasayatra.blogspot.com/ ------------------------------------------------------------ Add to your wisdom literature collection: https://iskconsv.com/book-store/?utm_source=youtube&utm_medium=video&utm_campaign=launch2025 https://www.bbtacademic.com/books/?utm_source=youtube&utm_medium=video&utm_campaign=launch2025 https://thefourquestionsbook.com/?utm_source=youtube&utm_medium=video&utm_campaign=launch2025 ------------------------------------------------------------ Join us live on Facebook: https://www.facebook.com/FanTheSpark/ Podcasts: https://podcasts.apple.com/us/podcast/sound-bhakti/id1132423868 For the latest videos, subscribe https://www.youtube.com/@FanTheSpark For the latest in SoundCloud: https://soundcloud.com/fan-the-spark ------------------------------------------------------------ #spiritualawakening #soul #spiritualexperience #spiritualpurposeoflife #spiritualgrowthlessons #secretsofspirituality #vaisesikaprabhu #vaisesikadasa #vaisesikaprabhulectures #spirituality #bhaktiyoga #krishna #spiritualpurposeoflife #krishnaspirituality #spiritualusachannel #whybhaktiisimportant #whyspiritualityisimportant #vaisesika #spiritualconnection #thepowerofspiritualstudy #selfrealization #spirituallectures #spiritualstudy #spiritualquestions #spiritualquestionsanswered #trendingspiritualtopics #fanthespark #spiritualpowerofmeditation #spiritualteachersonyoutube #spiritualhabits #spiritualclarity #bhagavadgita #srimadbhagavatam #spiritualbeings #kttvg #keepthetranscendentalvibrationgoing #spiritualpurpose

What if healing depends as much on your mindset and spirit as it does on your treatment plan? In this episode, host Jim Mann sits down with Dr. Francisco Contreras, who is the director, president, and chairman of Oasis of Hope Hospital in Tijuana, Mexico. He talks about his new book, The Art and Science of Undermining Cancer. Dr. Contreras shares the philosophical foundations his father built the hospital on 60 years ago, explains where chemotherapy and immunotherapy each earn their place in treatment, and dives into cutting-edge developments like dendritic cell vaccines and CAR T-cell therapy. But the heart of this conversation is bigger than protocols: it's about fear, faith, and why Dr. Contreras believes every improved outcome, big or small, is a miracle that has to be maintained. Jim also shares more of his own stage-four melanoma journey and how his mindset shifted after diagnosis.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

In this episode of The Ross Simmonds Show, Ross sits down with Talia Wolf, founder of GetUplift and author of Emotional Targeting, to unpack why customer emotion is now central to CRO, SEO, content marketing, and brand trust. They explore how marketers can move beyond surface-level analytics, use AI responsibly, uncover real customer motivations, and build messaging that converts by resonating with the right audience everywhere they show up online. Key Takeaways and Insights: 1. Why CRO Starts with the “Why,” Not Just the “Where” - Talia explains why tools like GA4 and Mixpanel can show where conversion problems happen, but not why people fail to convert. - The key to better leads and sales is understanding what information is missing, what feels risky, and what stops customers from taking action. - Strong conversion strategy starts with customer research, not random funnel tweaks or generic best practices. 2. Using AI Without Losing the Customer - AI can support gap analysis, data synthesis, and ideation, but it should not replace direct customer research. - Talia recommends gathering real inputs from surveys, interviews, Reddit threads, Facebook groups, sales calls, and chat transcripts before using AI. - Once you have authentic customer language, AI can become a strategic thinking partner rather than a shortcut to generic copy. 3. Emotional Targeting in B2B Marketing - Talia argues that B2B buying is often more emotional than B2C because professional decisions carry career, reputation, and budget risks. - Two major emotional clusters drive B2B decisions: social image and self-image. - Marketers should connect features to emotional value, such as helping buyers feel confident, trusted, respected, or prepared to impress leadership. 4. Trust, SEO, and CRO Are Converging - Ross and Talia discuss why SEO and CRO can no longer operate in silos. - Modern buyers research brands across Reddit, LinkedIn, YouTube, communities, AI tools, and search results before converting. - The new opportunity is to optimize everywhere by creating consistent, emotionally resonant messaging across owned and non-owned channels. 5. Better Messaging Comes from Better Listening - Talia shares how her team identifies misunderstandings, objections, and friction points through customer conversations and community research. - Real-world examples show how addressing skepticism directly can outperform polished but vague marketing claims. -  The best marketers resist the pressure to produce more and instead invest in customer insight, sharper positioning, and continuous testing. Resources & Tools:

A capa da edição 428 da Revista Crusoé traz "Cartão Laranja": Donald Trump prepara um novo tarifaço contra o Brasil e pode mexer no jogo eleitoral de 2026.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.    Transmissão ao vivo de segunda a sexta-feira às 12h no nosso canal do Youtube.  https://www.youtube.com/@OAntagonista  Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:  https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Inscreva-se no canal, ative as notificações e deixe sua opinião nos comentários!  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Tarifaço #Lula #Flávio #Eleições #Política #Debate #Estratégia #Trump #Disputa #Soberania #Economia #Governo #Oposição #Notícia #Campanha #YouTube #Podcast #Áudio #Viral #Internet

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the landscape of these dynamic sectors. Starting with Ipsen's Dysport, which has made notable strides in its Phase 3 trials for migraine prevention. The trials covered both episodic and chronic conditions, marking a first in the neurotoxin market. Dysport's success positions it as a formidable competitor to AbbVie's Botox, expanding therapeutic options for individuals battling migraine disorders. This achievement showcases the potential efficacy of botulinum toxin-based therapies in neurology and pain management, offering promising new avenues for patient care. In regulatory news, Boehringer Ingelheim has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for Jascayd, a small molecule PDE4B inhibitor with antifibrotic properties. This approval marks a significant milestone in the treatment of idiopathic and progressive pulmonary fibrosis. Jascayd's addition to the therapeutic arsenal offers new hope for managing this debilitating condition, emphasizing the ongoing efforts to improve patient outcomes through innovative treatments. The arena of business development sees HanChorBio partnering with InxMed to advance oncology research. By combining HCB101 with FAK inhibitors and FAP-targeted ADCs, this collaboration aims to leverage antibody and small molecule drug discovery techniques. The goal is to develop innovative cancer treatments that could redefine therapeutic approaches in oncology. Keenova Therapeutics has also reported success with Xiaflex for plantar fibromatosis. This enzyme injection therapy offers a novel approach by targeting collagen, thus providing an innovative solution for musculoskeletal conditions. Similarly, Fate Therapeutics' FT819, an off-the-shelf CAR-T therapy, has shown early promise in tackling treatment-resistant systemic sclerosis, underscoring the potential of cell therapies beyond oncology. Meanwhile, MindRank's successful Series B funding round of $52 million highlights the growing role of AI platforms in drug discovery. The funding will propel its AI-discovered oral GLP-1 obesity pill into Phase III trials, exemplifying how technology-driven solutions are gaining traction in addressing metabolic diseases like obesity. On the regulatory front, Saol Therapeutics has resubmitted SL1009 (DCA) to the FDA for pyruvate dehydrogenase complex deficiency. This submission underscores ongoing efforts to address rare metabolic disorders using small molecule therapies. Additionally, Sanofi's concessions to the EU regarding flu vaccine marketing illustrate the complexities of competitive dynamics and regulatory scrutiny within the vaccine market. However, not all developments are favorable. AstraZeneca and Ionis Pharmaceuticals faced a setback as their drug Wainua failed its Phase 3 trial for transthyretin-mediated amyloid cardiomyopathy. This outcome highlights the challenges inherent in developing effective treatments for complex cardiovascular conditions. Meanwhile, regulatory processes remain contentious as the FDA pauses its release of complete response letters amid debates over proprietary information disclosures. In another noteworthy development, GSK has terminated its $2.2 billion collaboration with Alector after underwhelming results from Alzheimer's drug trials. This decision highlights both financial implications and strategic shifts as companies reassess risk tolerance in neurodegenerative disease research. Conversely, Roche's success with its KRAS G12C inhibitor divarasib in Phase 3 lung cancer trials underscores the promise of precision medicine. Divarasib outperformed competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati, positioning Roche to potentially redefine standards of care based on genetic profiles. In a move reflecting industry trends towards collaboration and innovation risk-sharing models, AstraZeneca has partnered with Sino Biopharmaceutical on respiratory disease research. This strategic alliance represents a substantial investment aimed at expanding AstraZeneca's pipeline in respiratory therapeutics. Lastly, amidst these developments, psychedelic drugs are experiencing a renaissance in psychiatric care. Companies like Compass Pathways are pioneering clinical validation for their use in treating depression, signaling a potential paradigm shift from traditional SSRIs to newer therapeutic classes pending safety and efficacy data. Overall, these stories illustrate a dynamic interplay of scientific progress and regulatory navigation within the pharmaceutical and biotech sectors. While challenges persist—particularly in neurodegenerative disease treatment—the breakthroughs in oncology and metabolic disorder therapeutics offer hopeful prospects for improving patient care. As these industries continue evolving, integrating advanced technologies such as AI will likely play a pivotal role in shaping future therapeutic landscapes.Support the show

We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas? Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and then conventional T-cells. Neato. Polar-Go! or PolARGo? And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002 Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

In this episode of the Oncology Brothers podcast, we tackled two real-world challenging cases in diffuse large B-cell lymphoma (DLBCL) alongside two lymphoma experts — Dr. Matthew Lunning from the University of Nebraska and Dr. Gilles Salles from Memorial Sloan Kettering Cancer Center. The central question: when faced with relapsed or transformed aggressive B-cell lymphoma, how do you choose between CAR-T cell therapy and bispecific antibodies, and how do you get patients through this safely?   Key topics discussed included: The role of CAR-T cell therapy in early relapsed DLBCL based on ZUMA-7 and TRANSFORM trial data, and practical strategies for bridging and holding therapy pre- and post-apheresis to safely deliver treatment. A comparison of axicabtagene ciloleucel versus lisocabtagene maraleucel in terms of efficacy, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) rates, and outpatient feasibility. Management of transformed follicular lymphoma to double-hit DLBCL in the third-line setting, including the role of glofitamab, mosunetuzumab, polatuzumab, and epcoritamab as bridges to CAR-T cell therapy. The importance of early partnership between community oncologists and tertiary care centers to ensure patients access CAR-T and bispecific therapies in a timely manner. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Join us for this expert discussion on navigating the complex treatment landscape of relapsed and transformed aggressive B-cell lymphoma. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #DLBCL, #CARTTherapy, #BispecificAntibodies, #Hematology, #OncologyBrothers  

Le sujet fort de l'actualité foot du jour vu par Jérôme Rothen et la Dream Team.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Kirsty Hillier and Marco Ruella on their latest articles published in Blood. For "Predicting Development of Pediatric Chronic Immune Thrombocytopenia at Disease Onset Using a Statistical Risk Model", Dr. Hillier shares the potential benefits of incorporating this new model to enhance the care of the 1 in 4 patients who develop chronic ITP. As an alternative to current guidelines which advise providers to "wait and see", this online model determines patients who are at risk for chronic ITP, allowing for providers to make informed decisions on their continued care. In "Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies", Dr. Ruella explains how the treatment of T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective antitumor responses while preventing CAR T-cell fratricide. The team found that CD2 was a viable target, especially combined with a novel PD-1:CD2 switch receptor to remedy dysfunction caused by CD2 deletion.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

⏱️ Capítulos do vídeo00:00 Direito, Engenharia e Medicina não garantem mais riqueza00:47 A fonte dos dados: Receita Federal01:02 Pra quem é o vídeo de hoje01:20 Nº10 — Servidor de Auditoria Fiscal e Fiscalização02:28 Nº9 — Piloto de Avião / Comandante de Embarcação03:31 Nº8 — Servidor Bacen / CVM / SUSEP04:02 Nº7 — Médico06:21 Nº6 — Atleta Profissional08:33 Nº5 — Advogado do setor público / Procurador da Fazenda09:44 Nº4 — Diplomata10:17 Nº3 — Procurador / Promotor do Ministério Público11:28 Nº2 — Ministro / Juiz / Desembargador12:05 Nº1 — Titular de Cartório12:25 Conclusão: quem realmente fica rico no Brasil12:57 RC Wealth e RC Club

Have a comment? Send us a text! (We read all of them but can't reply). Email us: Will@faithfulpoliticspodcast.comWas the American Revolution really a fight for religious freedom? Katherine Carté, Professor of History at Southern Methodist University and author of Religion and the American Revolution: An Imperial History, helps separate the national myth from the historical record. Carté explains that the Revolution was not one simple story. It was both a break from British rule and the messy process of building a new United States. Religion mattered deeply, but not always in the way Americans assume. The conflict was not mainly Protestants fighting Britain for religious liberty. It was a political struggle over sovereignty, power, empire, and who had the right to rule. Carté shows how British imperial Protestantism connected Anglicans, Presbyterians, Congregationalists, missionaries, donors, and colonial institutions before the war disrupted that order. The conversation also explores religious establishments, loyalists, Catholics, Jews, religious tests, secular citizenship, and why “Was America founded as a Christian nation?” is too narrow a question.Guest BioKatherine Carté is Professor of History at Southern Methodist University, where she studies early American history, the eighteenth-century Atlantic world, the Age of Revolutions, early modern religion, and digital humanities. She is the author of Religion and the American Revolution: An Imperial History, published by the Omohundro Institute of Early American History and Culture and UNC Press, and Religion and Profit: Moravians in Early America. Her work helps explain how British imperial Protestantism shaped colonial life, how the American Revolution disrupted that religious and political order, and why the founding era cannot be reduced to simple claims about America being either Christian or secular.Book MentionedReligion and the American Revolution: An Imperial History by Katherine CartéBookshop.org: https://bookshop.org/a/112456/9781469662640Relevant Links & ResourcesKatherine Carté Faculty ProfileURL: https://people.smu.edu/kengel/ Support Sarah Stankorb's work and preorder Damned If She Does: Why Women Quit Church and What It Means for the Future of Religion, Releases September 15, 2026.  Bookshop.org: https://bookshop.org/a/112456/9798889837091Website: https://www.sarahstankorb.com/Support the showKeep the conversation going.Want to learn more about Faithful Politics, suggest a future guest, or connect with us directly?Visit our website:faithfulpoliticspodcast.comBrowse our bookstore, featuring books from many of our guests:faithfulpoliticspodcast.com/bookstoreSupport the show and help us keep these conversations going:patreon.com/cw/FaithfulPoliticsSubscribe for behind-the-scenes content, reflections, and updates:faithfulpolitics.substack.comContact the hosts:Josh Burtram, Faithful Host: Josh@faithfulpolitics.comWill Wright, Political Host: Will@faithfulpolitics.comFollow Faithful Politics:Instagram: faithful_politicsFacebook: FaithfulPoliticsPodcast

Nesse episódio, o PodDelas recebe Liz Macedo para um papoespecial — um ano e meio depois de sua primeira vez aqui!Ela, que transformou o "Arrume-se Comigo" em uma marcaregistrada da internet teen brasileira, abre o jogo sobrea fase mais intensa e reveladora da sua trajetória. Falasobre os bastidores do clipe com Anitta e Pedro Sampaio,sobre sua atuação como embaixadora da MBoom Beauty, sobreas polêmicas que enfrentou e sobre como está construindouma identidade própria longe dos rótulos.Além disso, conversamos sobre saúde mental, término derelacionamento, moda, a pressão de ser famosa aos 16 anose muito mais!Dá o play e vem assistir esse episódio especial! E temque se inscrever no canal! Clica aí!________________________Faça como a Anitta e aproveite as ofertas no 7.7 do Mercado Livre pra fazer suas comprittas. Escute a patroa e aproveite ofertas com até 70% off, frete grátis a partir de R$19 e parcelas de até 24x no cartão Mercado Pago. Corre pro app!

Earlier this year, Pew Research published the results of a study on religious diversity around the world. While the U.S. didn't even break the top 10 for most religiously diverse when all nations studied were taken into account, it ranked #1 in religious diversity out of the most populous countries.The United States certainly has a Christian tilt and a sizable population of nones. But, go to any major U.S. city and you'll spot kippahs, hijabs, turbans, and houses of worship for every major belief system on the planet.Despite the American ability to live alongside people who believe vastly different things than us, the U.S. has a horrid past with religious oppression—think of the KKK's treatment of Jewish people or the wipeout of indigenous people and their forced conversion to Christianity or the attacks on Muslims and Sikhs directly following 9/11.And while many prejudices take decades to extract the mainstream, a quick study of our history reveals that there is a clear pattern of America's ability to eventually accept religious differences.Over a century ago, the Catholics pouring in from, first, Ireland and, later, Italy, were near the bottom of the social hierarchy—pushed down by the majority protestant community who had been there much longer. Today, 6 of our 9 Supreme Court Justices are Catholic—only 2 are protestants, and one is Jewish. Pathways to success at the highest level are available to all in the U.S., even to those who, not very long ago, were seen as inferior.The U.S. has a long way to go in terms of equality and in the acceptance of all religions. But, if history repeats itself, it seems possible that even the faiths that are most discriminated against today, could also find great success here.The United States had its 250th birthday last week. And, in the last few episodes we have tried to understand the role of Christianity in America's founding. But what kinds of Christians were the first Americans? And what role did Catholics, Jews and Atheists play in the Revolution? Were there Muslims or Hindus on U.S. soil in 1776?To answer all of these questions and better understand the nature of religion at the time of America's founding I spoke with Katherine Carté. Carté is a History Professor at Southern Methodist University and wrote the book “Religion in The American Revolution: An Imperial History.”

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW's Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer research was a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

JOIN THE VALOR COFFEE COMMUNITY – Courses, Exclusive Videos, PDFs, Spreadsheets and more:⁠ ⁠https://community.valor.coffee?utm_source=spotify&utm_campaign=ep172Joey's been running our catering operation for a year and a half and has somehow not quit. In that time we went from 3 events a month to 30, hit $239k in revenue, and learned basically everything the hard way. We're breaking down real numbers, real pricing, permits, equipment, staffing, and how to actually get bookings. No fluff, just the stuff we wish someone told us before we started this epic journey. Come hang!This week's episode is brought to you by our friends at Odeko: Use our code VALOR10 for 10% off your first supply order! Hit the link below to sign up now:n https://portal.odeko.com/signup*If you purchase something through one of our links, we may be entitled to a share of the sale*Buy Valor Coffee: ⁠⁠https://valor.coffee/shop?utm_source=spotify&utm_campaign=ep172Watch on Youtube: ⁠⁠https://youtube.com/valorcoffee16⁠⁠Want to become a Wholesale Partner? Email us at wholesale@valor.coffee to set up an account!Want to send us coffee? Have a question you want to answer on the show? Send us an email to info@valor.coffeeWant to get your business in front of more people? We partnered with Local Eyes Growth to grow our business through SEO and the results have been incredible. Local Eyes is offering a FREE backlink ($300 value) to Valor Coffee Podcast listeners who partner through our exclusive link. Visit ⁠⁠https://localeyesgrowth.com/valor⁠⁠ to get the ball rolling!Follow the Valor Coffee Podcast on Instagram: ⁠⁠http://instagram.com/valorcoffeepod⁠⁠Follow Valor on Instagram: ⁠⁠http://instagram.com/valor.coffee⁠⁠Subscribe to Riley's YouTube Channel: ⁠⁠https://youtube.com/@rileywestbrook⁠⁠Follow Riley:  ⁠⁠https://instagram.com/rileywestbrook⁠⁠Follow Ross: ⁠⁠https://instagram.com/rosswalters⁠⁠Follow Ethan's Parody Account:  ⁠⁠https://instagram.com/ethanrivers777

Dr. GG deFiebre of SRNA spoke with Dr. Michael Levy and Dr. Benjamin Greenberg about CAR-T therapy for aquaporin-4-positive NMOSD. They described why targeting B cells may reduce aquaporin-4 antibodies over time and could enable long-term remission or reduced need for ongoing drugs [01:37]. The physicians outlined an autologous Phase 1 study at Mass General and UT Southwestern [07:02]. They discussed eligibility rationale and how lessons from this NMOSD-focused trial could inform future neuroimmune disorder research [09:10]. You can find more information about the trial here:https://clinicaltrials.gov/study/NCT07573332?cond=NMOSD&intr=CAR-T&viewType=Card&rank=1Benjamin M. Greenberg, MD, MHS is a Professor and the Cain Denius Scholar in Mobility Disorders in the Department of Neurology [https://utswmed.org/why-utsw/departments/neurology/] at UT Southwestern Medical Center in Dallas, Texas. He currently serves as the Vice Chair of Translational Research and Strategic Initiatives for the Department of Neurology. He is also the interim Director of the Multiple Sclerosis Center [https://utswmed.org/locations/aston/multiple-sclerosis-and-neuroimmunology-clinic/] and the Director of the Neurosciences Clinical Research Center. In addition, he serves as Director of the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program [https://www.childrens.com/specialties-services/specialty-centers-and-programs/neurology/demyelinating-disease-program] at Children's Medical Center.Dr. Greenberg earned his medical degree at Baylor College of Medicine before completing an internal medicine internship at Chicago's Rush Presbyterian-St. Luke's Medical Center. He performed his neurology residency at the Johns Hopkins School of Medicine. He also holds an M.H.S. in molecular microbiology and immunology from the Bloomberg School of Public Health, as well as a bachelor's degree in the history of medicine – both from Johns Hopkins. Prior to his recruitment to UT Southwestern in 2009, Dr. Greenberg was on the faculty of the Johns Hopkins Division of Neuroimmunology, serving as the Director of the Encephalitis Center and Co-Director of the nation's first dedicated Transverse Myelitis Center.Dr. Greenberg splits his clinical time between adult and pediatric patients at William P. Clements Jr. and Zale Lipshy University Hospitals, Parkland, and Children's Medical Center. His research focuses on better diagnosing, prognosticating, and treating demyelinating diseases and nervous system infections. He also coordinates clinical trials to evaluate new treatments to prevent neurologic damage and restore function to affected patients. Michael Levy, MD, PhD is a recognized neurologist with over 15 years of clinical and research expertise in rare neuroimmunological disorders. He established the Neuroimmunology Clinic and Research Laboratory at Massachusetts General Hospital and is the Research Director in the Division of Neuroimmunology and Neuroinfectious Disease. Previously, Dr. Levy was on the faculty at Johns Hopkins University and was the founding Director of their Neuromyelitis Optica Clinic. Clinically, Dr. Levy cares for patients with MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and idiopathic transverse myelitis (TM). Dr. Levy is also the principal investigator (PI) on numerous patient studies and drug trials for new and improved treatments for these disorders. In 2022, Dr. Levy became the lead principal investigator for the two worldwide clinical trials in MOG antibody disease. In the lab, Dr. Levy's research focuses on the development of animal models of NMO and MOG with the goal of tolerization as a sustainable long-term treatment. Dr. Levy has more than 200 peer-reviewed research articles, reviews and editorials, and 3 patents covering NMO tolerization therapy, TM diagnostics, and stem cell regeneration approaches.

El dolor articular es normal por la edad, el reuma es solo cosa de abuelos.

We discuss the mystery of the "cart ruts in stone" we visited while we were in Turkey; looking at video on the ground as well as drone footage of several large groups of well-preserved ruts in ancient volcanic tuff. Who made the ruts, when were they made, and how were they made? We address these questions and more, as well as reading emails from listeners who have their own possible answers. You can support us through Paypal or Patreon by heading over to our support page on our website: https://www.brothersoftheserpent.com/support   Chapters 00:00 Introduction to the Podcast and Setting the Scene 01:51 Space Weather News and Updates 04:21 Celebrating Wine Achievements and Science News 08:51 Innovations in Biointegrated Electronics 13:50 Exploring the Mystery of Cart Ruts 20:10 Investigating Cart Ruts in Turkey 25:23 Analyzing Drone Footage of Cart Ruts 39:03 Complexities of Cart Rut Formation 41:56 Understanding Cart Ruts and Their Mechanics 43:12 Exploring Theories Behind Cart Ruts 45:51 Analyzing Drainage and Irrigation Theories 47:47 The Role of Volcanic Tuff in Cart Rut Formation 50:25 Sleds, Plows, and Alternative Theories 52:51 Debunking Common Misconceptions 55:34 Creative Theories and Humor in Cart Rut Explanations 58:24 Flooding and Its Impact on Cart Ruts 01:01:10 The Boat Theory and Its Plausibility 01:04:10 Final Thoughts on Cart Ruts and Theories 01:15:56 Geological Comparisons and Ancient Technologies 01:19:01 Theories on Ruts: Boats, Vehicles, and Mining 01:30:02 Innovative Theories: Jet Skis and Shamirs 01:33:06 Mining Machines and Their Impact on Ruts 01:39:00 Clapham Junction: A Comparative Analysis 01:46:59 Conclusions and Future Discussions

Artificial intelligence may soon help clinicians prevent inpatient hypoglycemia before it occurs, while new decade-long follow-up data suggest CAR-T therapy may provide durable cures for selected patients with B-cell lymphoma. We also review a personalized statin muscle-risk calculator designed to improve shared decision-making and highlight new evidence supporting consistent resistance training as an important strategy for long-term type 2 diabetes prevention.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood. Dr. Zoller discusses "Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications.  Dr. Ribeiro discusses "A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial" and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.

Highlights from the PER® CME activity "Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Philippe Moreau, MD; Suzanne Lentzsch, MD, PhD; and Shaji Kumar, MD, discuss therapeutic innovations in the treatment of multiple myeloma, including frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates.Earn CME credit by completing the full accredited activity (available through June 5, 2027):https://www.gotoper.com/courses/medical-crossfire-turning-therapeutic-innovation-into-practicepersonalizing-care-in-multiple-myeloma-p2f5This podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Sanofi.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Stories from NYC! Catching up on the Discord! Live chat interactions! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In part two of my conversation with Nici Sweaney, we get into the full breakdown of her $1.5 million launch — every number, every decision, every behind-the-scenes moment that made it possible.This is the episode I've been so excited to share with you. Not because of the result — although it's extraordinary — but because of everything that went into it. The product build, the organic growth strategy, the messaging, the mindset going in, and what it actually felt like to be halfway around the world watching it unfold in real time. This is what scalable freedom actually looks like.In this episode we cover:— How Nici rebuilt her entire business from scratch in March before the launch — Why she pivoted the masterclass topic just three weeks before going live — The product-first philosophy that drove every decision — including shutting the business down for two weeks — Growing from 6,000 to 11,000 email subscribers in two weeks with zero ad spend — How 5,352 people registered for a free masterclass — when the goal was 1,000 — The 100% organic launch strategy: what she actually posted and how often — The mindset shift that changed everything: downgrading the goal from 100 members to 40 — The moment Ellie knew it was going to be massive — before Nici had any idea — Checking the numbers on the morning of a 3,000-person keynote — The phone call to Tom from a hotel taxi line: "We've just made $1 million" — Cart close in South America — and the final number that changed everything — What a $1.5M launch actually cost to run (the answer will surprise you) — A $160K day — made while sleeping in, going to the gym and having champagnes at a speaker dinner — What the real transformation of this launch was — and it wasn't the moneyLINKS:FREE GUIDE: Sell Out & Retain Mastermind Clients in 2026: https://ellieswift.com/mastermind2026Connect with Ellie on Instagram: https://instagram.com/elliehswiftSubscribe to Inside The Mastermind Newsletter: https://ellieswift.com/newsletterWatch on Youtube: https://www.youtube.com/@elliehswiftKeen to work together?Sell Out Your Mastermind: The Mastermind Model - https://ellieswift.com/modelBe Coached By Ellie to $500k+ : The Scalable Freedom Mastermind - https://ellieswift.com/scalablefreedom

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

This month, the gals keep the trend going and welcome Cory back to the stage (from the dining room) to discuss Canadian liberty, long drops, a different kind of catnip, transit disasters, mummy sourdough, and geocaching in the afterlife. Tune in for the June episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.